Is Compounded GLP-1 Legal in 2026?
By Chad Simpson · Updated May 6, 2026
How this page is reviewed
Editorially reviewed by GLP1CompareHub Editorial Team. We are an independent affiliate publisher — we are not licensed medical providers and this site does not deliver medical advice. Every claim on this page is sourced to a verifiable origin (peer-reviewed study, FDA documentation, live brand-site crawl, or our Katalys partner dashboard).
Affiliate disclosure: We earn a commission when you sign up with a provider through our links — at no extra cost to you. We do not rank providers by what they pay us; we rank by patient fit. Full disclosure. Read our methodology · medical disclaimer.
Yes — compounded GLP-1 from a licensed 503A pharmacy is legal with a valid physician prescription.
Patient-specific compounded semaglutide and tirzepatide from licensed 503A pharmacies remains legal under federal law as of May 2026. The legal framework is FDCA Section 503A. What is required: a valid prescription from a licensed physician and a licensed 503A compounding pharmacy.
The Timeline That Created the Confusion
If you’ve been following news about compounded GLP-1s, you can be forgiven for being confused. The headlines in 2024 and 2025 were real — but they described a specific enforcement target that does not apply to patient-specific 503A compounding. Here is what actually happened, in order:
2021–2023
GLP-1 drug shortage declared
FDA placed semaglutide (Ozempic, Wegovy) and later tirzepatide (Mounjaro, Zepbound) on its drug shortage list. Under FDCA Sections 503A and 503B, the shortage designation gave pharmacies broader legal authority to compound these medications.
Late 2024
FDA resolves the semaglutide shortage
FDA officially removed semaglutide from the shortage list. This narrowed the legal basis for 503B bulk compounding of semaglutide. Warning letters began going to some 503B facilities.
March–May 2025
FDA resolves tirzepatide shortage; enforcement against 503B manufacturers
FDA resolved the tirzepatide shortage. FDA issued enforcement actions targeting 503B outsourcing facilities that were continuing to bulk-manufacture compounded tirzepatide at scale without valid shortage justification. These are large industrial-scale manufacturers — not patient-specific pharmacies.
2025–2026 (current)
503A patient-specific compounding continues legally
503A patient-specific compounded semaglutide and tirzepatide with valid physician prescriptions continues to operate legally. The physician-prescription + patient-specific-compounding framework distinguishes 503A from the bulk 503B manufacturing that was targeted.
What Is Legal vs. What Is Not Legal
Legal (as of May 2026)
- Compounded semaglutide or tirzepatide prepared by a licensed 503A pharmacy for an individual patient
- Requires a valid prescription from a licensed physician, NP, or PA
- Pharmacy must be licensed in the patient's state
- Telehealth platforms with physician oversight + 503A pharmacy partners
- Patient-specific formulations (different concentration, add-ins like B12, etc.)
Not Legal / Gray Market
- Compounded GLP-1 sold without a physician prescription
- Bulk 503B manufacturing without valid drug shortage justification
- Compounded GLP-1 from unlicensed or unverified pharmacies
- Sources requiring no physician consultation at all
- Unusually low prices with no verifiable medical infrastructure (e.g., $20/month)
Key Protections to Look For as a Patient
If you are evaluating a telehealth provider for compounded GLP-1 medication, confirm all four of the following:
Valid prescription from a licensed physician
No medication should be dispensed until a licensed physician, NP, or PA has reviewed your health information and issued a prescription specifically for you. If a platform lets you order without any medical consultation, that is a red flag.
Licensed 503A pharmacy (not 503B)
The platform should be able to confirm that it uses a 503A licensed compounding pharmacy — not a 503B outsourcing facility. These are different legal categories with different regulatory histories. Ask directly if it is not stated clearly on the platform.
Pharmacy licensed in your state
Compounding pharmacies must hold valid non-resident pharmacy licenses in each state where they ship. Legitimate platforms will tell you which states they serve. If a platform ships nationally with no state restrictions mentioned, ask for their pharmacy license verification.
Reputable telehealth platform with a verifiable medical team
Legitimate providers will have identifiable licensed physicians on their team, verifiable state-level medical practice information, and transparent supply chain information. Look for publicly listed medical directors and pharmacy partners.
Red Flags for Gray-Market Sources
These are warning signs that a source may not be operating within the legal 503A framework:
- No physician consultation or prescription required — you can order directly
- Prices that seem too good to be true (e.g., $20–$30/month for tirzepatide)
- No state-by-state availability limitations listed anywhere on the site
- No identifiable licensed physician or medical director on the team
- Unable to identify which specific pharmacy fills the prescription
- No mention of 503A or compounding pharmacy licensing
- Ships internationally without a clear US pharmacy partner
Providers That Operate Within the Legal 503A Framework
The following platforms require physician prescriptions, use licensed 503A pharmacies, and operate within the legal framework for compounded GLP-1 medications:
TMates
Physician-supervised; competitive pricing; licensed 503A pharmacy partners.
MEDVi
Physician-led platform; explicit 503A pharmacy partnerships; transparent supply chain.
Eden Health
Bloodwork required at intake; strong regulatory transparency; physician-supervised prescribing.
Strut Health
Licensed physicians; 503A compounding pharmacy; state-licensed in all served markets.
Ivim Health
Physician-led; licensed 503A pharmacy; ongoing monitoring built into the program.
Frequently Asked Questions
Is compounded GLP-1 legal in 2026?
Yes. Compounded semaglutide and tirzepatide from a licensed 503A pharmacy with a valid physician prescription is legal under federal law as of May 2026. The legal framework is FDCA Section 503A, which permits patient-specific compounding by licensed pharmacies acting on a valid prescription.
Why did I hear that compounded GLP-1s were banned?
The confusion stems from 2025 FDA enforcement actions — but those actions targeted 503B outsourcing facilities that were bulk-manufacturing compounded GLP-1s at scale after the drug shortage was resolved. Patient-specific 503A compounding under a physician's prescription is a different legal category and was not banned.
What is the difference between legal and illegal compounded GLP-1?
Legal: compounded semaglutide or tirzepatide prepared by a licensed 503A pharmacy for an individual patient under a valid physician prescription. Illegal or gray-market: compounded GLP-1 sold without a physician prescription, sourced from unlicensed pharmacies, or bulk-manufactured by 503B facilities without valid shortage justification.
What protections should I look for when choosing a provider?
Four key protections: (1) a valid prescription from a licensed physician before any medication is dispensed, (2) use of a 503A licensed compounding pharmacy — not 503B, (3) the pharmacy is licensed in your state, (4) a reputable telehealth platform that is transparent about its pharmacy partners.
What are red flags for gray-market GLP-1 sources?
Major red flags: no physician consultation or prescription required, prices that are unusually low (e.g., $20/month for compounded tirzepatide), no verifiable pharmacy license information, no state-by-state availability restrictions, and no identifiable medical team.
Which telehealth providers operate within the legal 503A framework?
TMates, MEDVi, Eden Health, Strut Health, and Ivim Health all operate within the legal 503A framework — requiring physician prescriptions and using licensed 503A compounding pharmacies.
Related Articles
Related Guides
Continue your research with these related independent reviews.